B-Cell Surface Marker Analysis for Improvement of Rituximab Prophylaxis in ABO-Incompatible Adult Living Donor Liver Transplantation

Citations Over TimeTop 10% of 2007 papers

Abstract

Although the effectiveness of rituximab has been reported in ABO blood group (ABO)-incompatible (ABO-I) organ transplantation, the protocol is not yet established. We studied the impact of the timing of rituximab prophylaxis and the humoral immune response of patients undergoing ABO-I living donor liver transplantation (LDLT), focusing on clinicopathological findings and the B-cell subset. From July 2003 to December 2005, 30 adult patients were treated with hepatic artery infusion (HAI) protocol without splenectomy for ABO-I LDLT. A total of 17 patients were treated only with HAI (no prophylaxis), and the other 13 were treated with rituximab prophylaxis at various times prior to transplantation. For B-cell study of the spleen, another 4 patients undergoing ABO-I LDLT both with HAI after prophylaxis and eventual splenectomy, and 3 patients with ABO-compatible LDLT with splenectomy were enrolled. The mortality of the 30 patients with HAI, without splenectomy, and with/without rituximab prophylaxis was 33% and the main cause of death was sepsis. Peripheral blood B cells were completely depleted, anti-donor blood-type antibody titer was lower, and clinical and pathological antibody-mediated rejection was not observed in patients with prophylaxis earlier than 7 days before transplantation (early prophylaxis). Early rituximab prophylaxis significantly depleted B cells and memory B cells in the spleen but not in lymph nodes. On the other hand, B cells and memory B cells increased and memory B cells became dominant during antibody-mediated rejection. In conclusion, early prophylaxis with rituximab depletes B cells, including memory B cells, in the spleen and is associated with a trend toward lower humoral rejection rates and lower peak immunoglobulin (Ig)G titers in ABO-I LDLT patients.

Related Papers

• → Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab(2017)34 cited
• → ABO and Rh blood group genotypes in a cohort of Saudi stem cell donors(2018)11 cited
• [Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].(2013)
• [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].(2013)
• → Is the ABO Blood Group a Predictor of Renal Allograft Survival in ABO Identical Donor Recipients?(2021)